Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,982
archived clinical trials in
Endocrine

Eating Frequency and Visceral Adipose Tissue, Body Fat, and Obesity Risk in Hispanic College Freshmen
Freshman Health Study
Status: Enrolling
Updated:  10/20/2017
University of Texas at Austin
mi
from
Austin, TX
Eating Frequency and Visceral Adipose Tissue, Body Fat, and Obesity Risk in Hispanic College Freshmen
Freshman Health Study
Status: Enrolling
Updated: 10/20/2017
University of Texas at Austin
mi
from
Austin, TX
Click here to add this to my saved trials
Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia
Mini-Dose Glucagon for Adults With Type 1 Diabetes: A Study to Assess the Efficacy and Safety of Mini-dose Glucagon for Treatment of Non-severe Hypoglycemia in Adults With Type 1 Diabetes
Status: Enrolling
Updated:  10/23/2017
University of Colorado/Barbara Davis Center for Diabetes
mi
from
Aurora, CO
Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia
Mini-Dose Glucagon for Adults With Type 1 Diabetes: A Study to Assess the Efficacy and Safety of Mini-dose Glucagon for Treatment of Non-severe Hypoglycemia in Adults With Type 1 Diabetes
Status: Enrolling
Updated: 10/23/2017
University of Colorado/Barbara Davis Center for Diabetes
mi
from
Aurora, CO
Click here to add this to my saved trials
Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia
Mini-Dose Glucagon for Adults With Type 1 Diabetes: A Study to Assess the Efficacy and Safety of Mini-dose Glucagon for Treatment of Non-severe Hypoglycemia in Adults With Type 1 Diabetes
Status: Enrolling
Updated:  10/23/2017
Yale University of Medicine
mi
from
New Haven, CT
Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia
Mini-Dose Glucagon for Adults With Type 1 Diabetes: A Study to Assess the Efficacy and Safety of Mini-dose Glucagon for Treatment of Non-severe Hypoglycemia in Adults With Type 1 Diabetes
Status: Enrolling
Updated: 10/23/2017
Yale University of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia
Mini-Dose Glucagon for Adults With Type 1 Diabetes: A Study to Assess the Efficacy and Safety of Mini-dose Glucagon for Treatment of Non-severe Hypoglycemia in Adults With Type 1 Diabetes
Status: Enrolling
Updated:  10/23/2017
Joslin Diabetes Center
mi
from
Boston, MA
Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia
Mini-Dose Glucagon for Adults With Type 1 Diabetes: A Study to Assess the Efficacy and Safety of Mini-dose Glucagon for Treatment of Non-severe Hypoglycemia in Adults With Type 1 Diabetes
Status: Enrolling
Updated: 10/23/2017
Joslin Diabetes Center
mi
from
Boston, MA
Click here to add this to my saved trials
Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia
Mini-Dose Glucagon for Adults With Type 1 Diabetes: A Study to Assess the Efficacy and Safety of Mini-dose Glucagon for Treatment of Non-severe Hypoglycemia in Adults With Type 1 Diabetes
Status: Enrolling
Updated:  10/23/2017
SUNY Upstate Medical University
mi
from
Syracuse, NY
Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia
Mini-Dose Glucagon for Adults With Type 1 Diabetes: A Study to Assess the Efficacy and Safety of Mini-dose Glucagon for Treatment of Non-severe Hypoglycemia in Adults With Type 1 Diabetes
Status: Enrolling
Updated: 10/23/2017
SUNY Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia
Mini-Dose Glucagon for Adults With Type 1 Diabetes: A Study to Assess the Efficacy and Safety of Mini-dose Glucagon for Treatment of Non-severe Hypoglycemia in Adults With Type 1 Diabetes
Status: Enrolling
Updated:  10/23/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia
Mini-Dose Glucagon for Adults With Type 1 Diabetes: A Study to Assess the Efficacy and Safety of Mini-dose Glucagon for Treatment of Non-severe Hypoglycemia in Adults With Type 1 Diabetes
Status: Enrolling
Updated: 10/23/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Screening Protocol for Subjects Being Evaluated for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Protocols
Screening Protocol for Subjects Being Evaluated for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Protocols
Status: Enrolling
Updated:  10/26/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Screening Protocol for Subjects Being Evaluated for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Protocols
Screening Protocol for Subjects Being Evaluated for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Protocols
Status: Enrolling
Updated: 10/26/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated:  10/30/2017
Chinle Comprehensive Health Care Facility
mi
from
Chinle, AZ
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated: 10/30/2017
Chinle Comprehensive Health Care Facility
mi
from
Chinle, AZ
Click here to add this to my saved trials
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated:  10/30/2017
Tsehootsooi Medical Center
mi
from
Fort Defiance, AZ
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated: 10/30/2017
Tsehootsooi Medical Center
mi
from
Fort Defiance, AZ
Click here to add this to my saved trials
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated:  10/30/2017
Kayenta Health Center
mi
from
Kayenta, AZ
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated: 10/30/2017
Kayenta Health Center
mi
from
Kayenta, AZ
Click here to add this to my saved trials
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated:  10/30/2017
Crownpoint Health Center Facility
mi
from
Crownpoint, NM
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated: 10/30/2017
Crownpoint Health Center Facility
mi
from
Crownpoint, NM
Click here to add this to my saved trials
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated:  10/30/2017
Gallup Indian Medical Center
mi
from
Gallup, NM
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated: 10/30/2017
Gallup Indian Medical Center
mi
from
Gallup, NM
Click here to add this to my saved trials
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated:  10/30/2017
Northern Navajo Medical Center
mi
from
Shiprock, NM
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Status: Enrolling
Updated: 10/30/2017
Northern Navajo Medical Center
mi
from
Shiprock, NM
Click here to add this to my saved trials
TRADE-Testosterone Replacement and Dutasteride Effectiveness
Testosterone Replacement and Dutasteride Effectiveness (TRADE)
Status: Enrolling
Updated:  10/30/2017
VA Puget Sound Health Care System
mi
from
Seattle, WA
TRADE-Testosterone Replacement and Dutasteride Effectiveness
Testosterone Replacement and Dutasteride Effectiveness (TRADE)
Status: Enrolling
Updated: 10/30/2017
VA Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis
A Phase II, Multi-Center, Open Label Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis (HUM 04-36)
Status: Enrolling
Updated:  11/1/2017
Wake Forest University Health Sciences, Dermatology
mi
from
Winston-Salem, NC
Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis
A Phase II, Multi-Center, Open Label Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis (HUM 04-36)
Status: Enrolling
Updated: 11/1/2017
Wake Forest University Health Sciences, Dermatology
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects
The Effect of TRADJENTA ® (LINAGLIPTIN) on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects
Status: Enrolling
Updated:  11/2/2017
ECMC Ambulatory Center, 3rd Floor
mi
from
Buffalo, NY
The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects
The Effect of TRADJENTA ® (LINAGLIPTIN) on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects
Status: Enrolling
Updated: 11/2/2017
ECMC Ambulatory Center, 3rd Floor
mi
from
Buffalo, NY
Click here to add this to my saved trials
Exercise Program in Women With Metabolic Syndrome
The Effect of Mixed Aerobic and Strength Training Program on Physical Fitness and Cerebrovascular Function in Older Women With Metabolic Syndrome: A Pilot Study With Randomized Control Trial (RCT) Design
Status: Enrolling
Updated:  11/2/2017
Beth Israel Deaconess Medical Center, Harvard University
mi
from
Boston, MA
Exercise Program in Women With Metabolic Syndrome
The Effect of Mixed Aerobic and Strength Training Program on Physical Fitness and Cerebrovascular Function in Older Women With Metabolic Syndrome: A Pilot Study With Randomized Control Trial (RCT) Design
Status: Enrolling
Updated: 11/2/2017
Beth Israel Deaconess Medical Center, Harvard University
mi
from
Boston, MA
Click here to add this to my saved trials
Protein, Amino Acids & Insulin & Glucagon Secretion in Humans
The Effect of Ingestion of Foods on the Plasma Glucose and Insulin Response in Subjects With Type 2 Diabetes: Protein, Amino Acids & Insulin & Glucagon Secretion in Humans
Status: Enrolling
Updated:  11/6/2017
Minneapolis VA Health Care System
mi
from
Minneapolis, MN
Protein, Amino Acids & Insulin & Glucagon Secretion in Humans
The Effect of Ingestion of Foods on the Plasma Glucose and Insulin Response in Subjects With Type 2 Diabetes: Protein, Amino Acids & Insulin & Glucagon Secretion in Humans
Status: Enrolling
Updated: 11/6/2017
Minneapolis VA Health Care System
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
Sierra Medical Research
mi
from
Clovis, CA
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
Sierra Medical Research
mi
from
Clovis, CA
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
University of California, San Diego
mi
from
San Diego, CA
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
University of California at San Francisco
mi
from
San Francisco, CA
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
Arnold Palmer Hospital for Children
mi
from
Orlando, FL
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
Arnold Palmer Hospital for Children
mi
from
Orlando, FL
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
Larry C. Deeb, M.D., P.A.
mi
from
Tallahassee, FL
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
Larry C. Deeb, M.D., P.A.
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
Nancy Wright, M.D., P.A. Pediatric Endocrinology
mi
from
Tallahassee, FL
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
Nancy Wright, M.D., P.A. Pediatric Endocrinology
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
University of South Florida
mi
from
Tampa, FL
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
Van Meter Pediatric Endocrinology, P.C.
mi
from
Atlanta, GA
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
Van Meter Pediatric Endocrinology, P.C.
mi
from
Atlanta, GA
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
Riley Hospital for Children
mi
from
Indianapolis, IN
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
Barry J. Reiner MD
mi
from
Baltimore, MD
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
Barry J. Reiner MD
mi
from
Baltimore, MD
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
Baystate Medical Center Children's Hospital
mi
from
Springfield, MA
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
Baystate Medical Center Children's Hospital
mi
from
Springfield, MA
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
Children's Mercy Hospital
mi
from
Kansas City, MO
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
Morristown Medical Center
mi
from
Morristown, NJ
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
Morristown Medical Center
mi
from
Morristown, NJ
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
Women & Children's Hospital
mi
from
Buffalo, NY
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
Women & Children's Hospital
mi
from
Buffalo, NY
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
Winthrop University Hospital
mi
from
Mineola, NY
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
Winthrop University Hospital
mi
from
Mineola, NY
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
Diabetes & Endocrine Center for Children and Young Adults
mi
from
Sleepy Hollow, NY
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
Diabetes & Endocrine Center for Children and Young Adults
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
Cleveland Clinic
mi
from
Cleveland, OH
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
Nationwide Children's Hospital
mi
from
Columbus, OH
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated:  11/6/2017
University of Washington, Seattle Children's Hospital
mi
from
Seattle, WA
Versartis Long-Term Safety Study of Somavaratan
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Status: Enrolling
Updated: 11/6/2017
University of Washington, Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Effect of Closed Loop Glucose Control on Exercise-Associated Hypoglycemia
Effect of Closed Loop Glucose Control on Exercise-Associated Hypoglycemia
Status: Enrolling
Updated:  11/9/2017
Yale Pediatrics Diabetes Research
mi
from
New Haven, CT
Effect of Closed Loop Glucose Control on Exercise-Associated Hypoglycemia
Effect of Closed Loop Glucose Control on Exercise-Associated Hypoglycemia
Status: Enrolling
Updated: 11/9/2017
Yale Pediatrics Diabetes Research
mi
from
New Haven, CT
Click here to add this to my saved trials
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Torrance, CA
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Lexington, KY
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Boston, MA
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Ann Arbor, MI
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Omaha, NE
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
New York, NY
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Portland, OR
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Little Rock, AR
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials